



INFERTILITY
Prior Authorization Request

Send completed form to: Case Review Unit, CVS Caremark Prior Authorization Fax: 1-866-249-6155

CVS Caremark administers the prescription benefit plan for the patient identified. This patient's benefit plan requires prior authorization for certain medications in order for the drug to be covered. To make an appropriate determination, providing the most accurate diagnosis for the use of the prescribed medication is necessary. **Please respond below and fax this form to CVS Caremark toll-free at 1-866-249-6155.** If you have questions regarding the prior authorization, please contact CVS Caremark at **1-866-814-5506**. For inquiries or questions related to the patient's eligibility, drug copay or medication delivery; please contact the Specialty Customer Care Team: CaremarkConnect® 1-800-237-2767.

The recipient of this fax may make a request to opt-out of receiving telemarketing fax transmissions from CVS Caremark. There are numerous ways you may opt-out: The recipient may call the toll-free number at 877-265-2711, at any time, 24 hours a day/7 days a week. The recipient may also send an opt-out request via email to do_not_call@cvscaremark.com. An opt out request is only valid if it (1) identifies the number to which the request relates, and (2) if the person/entity making the request does not, subsequent to the request, provide express invitation or permission to CVS Caremark to send facsimile advertisements to such person/entity at that particular number. CVS Caremark is required by law to honor an opt-out request within thirty days of receipt.

PATIENT INFORMATION

Date: _____
Name: _____
ID: _____
Date of Birth: _____
Request Initiated For: _____

PRESCRIBER INFORMATION

Name: _____
Office Telephone: _____
Office Fax: _____
Specialty: _____
NPI#: _____

DRUG(S) PRESCRIBED *Please select the drug(s) that will be prescribed throughout the course of treatment.*

- | | | | | | |
|-----------------------------------|------------------------------------|---------------------------------------|----------------------------------|--------------------------------------|---|
| <input type="checkbox"/> Gonal-f* | <input type="checkbox"/> Cetrotide | <input type="checkbox"/> ganirelix | <input type="checkbox"/> Ovidrel | <input type="checkbox"/> hCG | <input type="checkbox"/> leuprolide acetate |
| <input type="checkbox"/> Menopur | <input type="checkbox"/> Novarel | <input type="checkbox"/> Follistim AQ | <input type="checkbox"/> Pregnyl | <input type="checkbox"/> Other _____ | |

**Gonal-f is the preferred product over Follistim AQ for your patient's health plan.*

PATIENT DIAGNOSIS/PROCEDURE & ICD-10 CODE

- Ovulation induction (e.g., intrauterine insemination [IUI])
- Assisted reproductive technology (e.g., in vitro fertilization [IVF], frozen embryo transfer, gamete intrafallopian transfer [GIFT], zygote intrafallopian transfer [ZIFT], intracytoplasmic sperm injection [ICSI])
- Prepubertal cryptorchidism
- Hypogonadotropic hypogonadism
- Other _____

ICD-10: _____

PREFERRED DRUG *Please complete this section if Follistim AQ is being prescribed.*

1. The preferred product for your patient's health plan is Gonal-f. Can the patient's treatment be switched to Gonal-f? ***If Yes, fax a new prescription to the pharmacy and skip to next section.*** Yes No
2. Is this request for continuation of therapy with the requested product? Yes No *If No, skip to #4*
3. Is the patient currently receiving the requested product through samples or a manufacturer's patient assistance program? If unknown, answer 'Yes'. Yes No *If No, skip to next section.*
4. Does the patient have a documented contraindication to Gonal-f or any of its drug components?
ACTION REQUIRED: If Yes, attach supporting chart note(s) and skip to next section. Yes No
5. Has the patient experienced a documented intolerable adverse event to Gonal-f? ***ACTION REQUIRED: If Yes, attach supporting chart note(s).*** Yes No

Note: This fax may contain medical information that is privileged and confidential and is solely for the use of individuals named above. If you are not the intended recipient you hereby are advised that any dissemination, distribution, or copying of this communication is prohibited. If you have received the fax in error, please immediately notify the sender by telephone and destroy the original fax message. Infertility PDPD SGM - 1/2019.

MEDICAL BENEFIT PLAN APPROVAL INFORMATION

1. Is coverage for the drug(s) being requested for a procedure that has been approved by the patient's medical benefit plan?
 Yes - Indicate the medical authorization number: _____
 No
 Not applicable, patient's medical benefit plan does not require precertification for the requested procedure
2. What type of procedure has been approved by the medical benefit plan **OR** the patient will be undergoing?
If procedure indicated below has been previously approved by the plan, no further questions.
 Ovulation induction (e.g., intrauterine insemination [IUI])
 Assisted reproductive technology (e.g., in vitro fertilization [IVF], frozen embryo transfer, gamete intrafallopian transfer [GIFT], zygote intrafallopian transfer [ZIFT], intracytoplasmic sperm injection [ICSI])
 Mature oocyte cryopreservation
 Embryo cryopreservation
 Preimplantation genetic diagnosis
 Other _____

DIAGNOSIS/PROCEDURE SPECIFIC QUESTIONS

OVULATION INDUCTION, ASSISTED REPRODUCTIVE TECHNOLOGY - FOLLISTIM AQ, GONAL-F, MENOPUR

1. How many cycles of clomiphene citrate (Clomid, Serophene) has the patient completed? _____ cycles
If three or more cycles have been completed, no further questions.
2. Does the patient have a risk factor for poor ovarian response to clomiphene?
If Yes, no further questions Yes No
3. Does the patient have a contraindication or exclusion to therapy with clomiphene? Yes No

OVULATION INDUCTION, ASSISTED REPRODUCTIVE TECHNOLOGY - LEUPROLIDE ACETATE

1. What is the intent of therapy?
 Inhibition of premature luteinizing hormone (LH) surges
 Ovulation trigger
 Other _____

OVULATION INDUCTION, ASSISTED REPRODUCTIVE TECHNOLOGY - CETROTIDE, GANIRELIX

1. What is the intent of therapy?
 Inhibition of premature luteinizing hormone (LH) surges
 Other _____

HYPOGONADOTROPIC HYPOGONADISM

1. Does the patient have a low pretreatment testosterone level? Yes No
2. Does the patient have:
 Low or low-normal follicle stimulating hormone (FSH) level
 Low or low-normal luteinizing hormone (LH) level
 Neither

AUTHORIZATION

I attest that this information is accurate and true, and that documentation supporting this information is available for review if requested by CVS Caremark or the benefit plan sponsor.

X _____

Prescriber or Authorized Signature

Date (mm/dd/yy)

If additional information is needed, the person below will be contacted:

Office Contact Person: _____

Contact Phone: _____

Note: This fax may contain medical information that is privileged and confidential and is solely for the use of individuals named above. If you are not the intended recipient you hereby are advised that any dissemination, distribution, or copying of this communication is prohibited. If you have received the fax in error, please immediately notify the sender by telephone and destroy the original fax message. Infertility PDPD SGM - 1/2019.

CVS Caremark Prior Authorization • 2211 Sanders Road NBT-6 • Northbrook, IL 60062

Phone: 1-866-814-5506 • Fax: 1-866-249-6155 • www.caremark.com

Note: This fax may contain medical information that is privileged and confidential and is solely for the use of individuals named above. If you are not the intended recipient you hereby are advised that any dissemination, distribution, or copying of this communication is prohibited. If you have received the fax in error, please immediately notify the sender by telephone and destroy the original fax message. Infertility PDPD SGM - 1/2019.

CVS Caremark Prior Authorization • 2211 Sanders Road NBT-6 • Northbrook, IL 60062
Phone: 1-866-814-5506 • Fax: 1-866-249-6155 • www.caremark.com